自己幹細胞および非幹細胞ベースの世界市場レポート 2025年

自己幹細胞および非幹細胞ベース市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR16.1％で210億7,000万米ドルに成長します。予測期間の成長は、対象疾患の有病率上昇、老年人口の増加、神経変性疾患の有病率上昇、がん症例数の増加、皮膚移植需要の増加、再生医療に対する意識の高まり、主要企業間の提携やパートナーシップ、承認された治療法に対する償還の改善などに起因すると考えられます。予測期間における主な動向としては、人工知能と機械学習の統合、既製の同種幹細胞製品の開発、償還政策の拡大、新規生体材料の採用、細胞製造技術の進歩、自家幹細胞療法の採用、遺伝子編集技術の統合などが挙げられます。

個別化治療に対する需要の高まりが、当面の間、自己幹細胞・非幹細胞治療市場の成長を牽引することになると思われます。個別化治療とは、個人の遺伝学、ライフスタイル、嗜好に基づいて、利益を最大化し、副作用を最小化するように調整された治療を指します。個別化治療が急増している背景には、遺伝学や技術の進歩により、副作用を抑えながらより精密で効果的な治療が可能になったこと、個別化治療に対する患者の嗜好が高まっていること、ヘルスケアにおけるコスト削減の可能性など、いくつかの要因が考えられます。個別化治療は、各個人の遺伝的特徴や健康状態に合わせて、自家幹細胞や非幹細胞を用いた治療を最適化するもので、治療成績の向上や合併症の減少につながります。例えば、2022年に個別化医療連合が発表したデータによると、12の個別化新薬の承認は、新たに承認された治療法全体の約34％を占め、以前より大幅に増加したことを示しています。したがって、個別化治療に対する需要の高まりは、自家幹細胞および非幹細胞ベースの治療市場の原動力となっています。

自己幹細胞・非幹細胞治療市場の有力企業は、個別化がん治療戦略を強化するため、腫瘍由来自己T細胞免疫療法の開発に注力しています。腫瘍由来自己T細胞免疫療法は、患者の腫瘍からT細胞を抽出し、実験室で増殖・活性化させ、患者に再導入することで、がん細胞を特異的に標的とし根絶する免疫系の能力を高めるものです。例えば、2024年2月、米国のバイオテクノロジー企業であるアイオバンス・バイオセラピューティクス社は、成人メラノーマ患者の治療に適応のある初の細胞療法であるアムタグビ（リフィリューセル）について、食品医薬品局から早期承認を取得しました。腫瘍由来の自己T細胞免疫療法であるリフィリューセルは、腫瘍浸潤リンパ球（TIL）として知られる患者の自然発生免疫細胞から構成され、がんを認識し、がんと闘う免疫系の能力をより効果的に高める。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界自己幹細胞および非幹細胞ベース PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の自己幹細胞および非幹細胞ベース市場：成長率分析
• 世界の自己幹細胞および非幹細胞ベース市場の実績：規模と成長, 2019-2024
• 世界の自己幹細胞および非幹細胞ベース市場の予測：規模と成長, 2024-2029, 2034F
• 世界自己幹細胞および非幹細胞ベース総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の自己幹細胞および非幹細胞ベース市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自己幹細胞
• 自己非幹細胞
• その他のタイプ
• 世界の自己幹細胞および非幹細胞ベース市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん
• 神経変性疾患
• 心血管疾患
• 整形外科疾患
• その他の用途
• 世界の自己幹細胞および非幹細胞ベース市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外来手術センター
• 調査施設
• その他のエンドユーザー
• 世界の自己幹細胞および非幹細胞ベース市場自己幹細胞の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 造血幹細胞
• 間葉系幹細胞
• 神経幹細胞
• 内皮幹細胞
• 世界の自己幹細胞および非幹細胞ベース市場自己非幹細胞の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多血小板血漿（PRP）
• 脂肪由来細胞
• 末梢血細胞
• 世界の自己幹細胞および非幹細胞ベース市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エクソソームを用いた治療法
• 組織工学構造物

第7章 地域別・国別分析

• 世界の自己幹細胞および非幹細胞ベース市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の自己幹細胞および非幹細胞ベース市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 自己幹細胞および非幹細胞ベース市場：競合情勢
• 自己幹細胞および非幹細胞ベース市場：企業プロファイル
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Stemcell Technologies Inc.
• Dendreon Corporation
• Vericel Corporation
• Sangamo Therapeutics Inc.
• NEOSTEM
• Orgenesis Inc.
• Adaptimmune Therapeutics
• Stempeutics Research Pvt Ltd.
• MEDIPOST
• Castle Creek Biosciences Inc.
• BrainStorm Cell Limited
• Athersys Inc.
• Cytori Therapeutics Inc.
• Opexa Therapeutics
• Gamida Cell

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 自己幹細胞および非幹細胞ベース市場2029：新たな機会を提供する国
• 自己幹細胞および非幹細胞ベース市場2029：新たな機会を提供するセグメント
• 自己幹細胞および非幹細胞ベース市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Autologous stem cell and non-stem cell-based therapies encompass treatments that utilize a patient's own cells to repair, replace, or regenerate damaged tissues and organs. In autologous stem cell therapies, stem cells are extracted from the patient, expanded or modified, and reintroduced to facilitate healing and regeneration. Non-stem cell-based therapies, on the other hand, utilize different types of cells, such as immune cells or tissue-specific cells, to achieve similar therapeutic objectives. These personalized approaches aim to mitigate the risk of immune rejection and enhance treatment efficacy for conditions such as cancer, autoimmune diseases, and degenerative disorders.

The primary types of autologous stem cell and non-stem cell-based therapies include autologous stem cells, autologous non-stem cells, and others. Autologous stem cells are derived from the patient's own body and utilized in medical therapies to facilitate the healing of damaged tissue or organs. They find application across various fields including cancer treatment, neurodegenerative disorders, cardiovascular disease, orthopedic conditions, and others, and are utilized by hospitals, ambulatory surgical centers, research facilities, and other healthcare institutions.

The autologous stem cell and non-stem cell based therapies market research report is one of a series of new reports from The Business Research Company that provides autologous stem cell and non-stem cell based therapies market statistics, including the autologous stem cell and non-stem cell based therapies industry global market size, regional shares, competitors with autologous stem cell and non-stem cell based therapies market share, detailed autologous stem cell and non-stem cell based therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the autologous stem cell and non-stem cell based therapies industry. These autologous stem cell and non-stem cell based therapies market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The autologous stem cell and non-stem cell based therapies market size has grown rapidly in recent years. It will grow from $9.96 billion in 2024 to $11.59 billion in 2025 at a compound annual growth rate (CAGR) of 16.5%. The growth in the historic period can be attributed to increased prevalence of cancer and diabetes, increased numbers of geriatric individuals, growing healthcare awareness, rise in research and development activities, increased numbers of clinical trials, Increased regulatory approval.

The autologous stem cell and non-stem cell based therapies market size is expected to see rapid growth in the next few years. It will grow to $21.07 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to rising prevalence of targeted diseases, an increasing geriatric population, rising prevalence of neurodegenerative diseases, growing number of cancer cases, increasing demand for skin transplantation, increasing awareness about regenerative medicine, collaborations and partnerships among key players, improving reimbursement for approved therapies. Major trends in the forecast period include the integration of artificial intelligence and machine learning, development of off-the-shelf allogeneic stem cell products, expansion of reimbursement policies, adoption of novel biomaterials, advancements in cell manufacturing technologies, adoption of autologous stem cell therapies, integration of gene editing technologies.

The increasing demand for personalized therapies is set to drive the growth of the autologous stem cell and non-stem cell-based therapies market in the foreseeable future. Personalized therapies refer to medical treatments tailored to maximize benefits and minimize adverse effects based on individual genetics, lifestyle, and preferences. This surge in personalized therapies can be attributed to several factors, including advancements in genetics and technology enabling more precise and effective treatments with reduced side effects, growing patient preference for customized care, and the potential for cost savings in healthcare. Personalized therapies optimize the utilization of autologous stem cell and non-stem cell-based treatments by tailoring them to the unique genetic and health characteristics of each individual, resulting in improved outcomes and fewer complications. For example, data from the Personalized Medicine Coalition in 2022 indicated that the approval of 12 new personalized medicines accounted for around 34% of all newly approved therapies, signaling a significant increase from previous years. Hence, the increasing demand for personalized therapies serves as a driving force for the autologous stem cell and non-stem cell-based therapies market.

Prominent companies in the autologous stem cell and non-stem cell-based therapies market are focusing on the development of tumor-derived autologous T cell immunotherapy to enhance personalized cancer treatment strategies. Tumor-derived autologous T cell immunotherapy involves extracting T cells from a patient's tumor, expanding and activating them in the laboratory, and reintroducing them into the patient to boost the immune system's ability to target and eradicate cancer cells specifically. For instance, in February 2024, Iovance Biotherapeutics, a US-based biotechnology company, obtained accelerated approval from the Food and Drug Administration for Amtagvi (lifileucel), the first cellular therapy indicated for treating adult patients with melanoma. Lifileucel, a tumor-derived autologous T-cell immunotherapy, consists of a patient's naturally occurring immune cells known as tumor-infiltrating lymphocytes (TILs), enhancing the immune system's ability to recognize and combat cancer more effectively.

In April 2022, Metcela Inc., a Japan-based biotechnology company, acquired Japan Regenerative Medicine Co. Ltd. (JRM) for an undisclosed sum. Through this acquisition, Metcela Inc. aims to expand its portfolio with an autologous cell product for pediatric congenital heart disease and leverage synergies in manufacturing and sales systems for a wide range of cardiac therapies. Japan Regenerative Medicine Co. Ltd. (JRM) specializes in developing regenerative medicine therapies for pediatric congenital heart diseases and offers services related to stem cell therapy.

Major companies operating in the autologous stem cell and non-stem cell based therapies market are Bayer AG, Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck & Co. Inc., Stemcell Technologies Inc., Dendreon Corporation, Vericel Corporation, Sangamo Therapeutics Inc., NEOSTEM, Orgenesis Inc., Adaptimmune Therapeutics, Stempeutics Research Pvt Ltd., MEDIPOST, Castle Creek Biosciences Inc., BrainStorm Cell Limited, Athersys Inc., Cytori Therapeutics Inc., Opexa Therapeutics, Gamida Cell, Regen BioPharma Inc., RepliCel Life Sciences, InGeneron Inc., BioCardia Inc., ReNeuron Group

North America was the largest region in the autologous stem cell and non-stem cell based therapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous stem cell and non-stem cell based therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the autologous stem cell and non-stem cell based therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The autologous stem cell and non-stem cell-based therapies market consists of revenues earned by entities by providing services such as patient evaluation, cell collection and processing, genetic modification, quality control, cell storage, infusion, post-treatment monitoring, regulatory compliance, and patient support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The autologous stem cell and non-stem cell-based therapies market also includes sales of platelet-rich plasma (PRP) therapy, autologous fibroblast injection, autologous dendritic cell therapy, and tumor-derived autologous T cell immunotherapy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Autologous Stem Cell And Non-Stem Cell Based Therapies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on autologous stem cell and non-stem cell based therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for autologous stem cell and non-stem cell based therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The autologous stem cell and non-stem cell based therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Autologous Stem Cells; Autologous Non-Stem Cells; Other Types
• 2) By Application: Cancer; Neurodegenerative Disorders; Cardiovascular Disease; Orthopedic Diseases; Other Applications
• 3) By End-User: Hospitals; Ambulatory Surgical Centers; Research Facilities; Other End Users
• Subsegments:
• 1) By Autologous Stem Cells: Hematopoietic Stem Cells; Mesenchymal Stem Cells; Neural Stem Cells; Endothelial Stem Cells
• 2) By Autologous Non-Stem Cells: Platelet-Rich Plasma (Prp); Adipose-Derived Cells; Peripheral Blood Cells
• 3) By Other Types: Exosome-Based Therapies; Tissue-Engineered Constructs
• Companies Mentioned: Bayer AG; Novartis AG; Takeda Pharmaceutical Company Limited; Gilead Sciences Inc.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Characteristics

3. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Trends And Strategies

4. Autologous Stem Cell And Non-Stem Cell Based Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Growth Analysis And Strategic Analysis Framework

• 5.1. Global Autologous Stem Cell And Non-Stem Cell Based Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market Growth Rate Analysis
• 5.4. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Total Addressable Market (TAM)

6. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Segmentation

• 6.1. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cells
• Autologous Non-Stem Cells
• Other Types
• 6.2. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Neurodegenerative Disorders
• Cardiovascular Disease
• Orthopedic Diseases
• Other Applications
• 6.3. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Research Facilities
• Other End Users
• 6.4. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Sub-Segmentation Of Autologous Stem Cells, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hematopoietic Stem Cells
• Mesenchymal Stem Cells
• Neural Stem Cells
• Endothelial Stem Cells
• 6.5. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Sub-Segmentation Of Autologous Non-Stem Cells, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Platelet-Rich Plasma (PRP)
• Adipose-Derived Cells
• Peripheral Blood Cells
• 6.6. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exosome-Based Therapies
• Tissue-Engineered Constructs

7. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Regional And Country Analysis

• 7.1. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 8.1. Asia-Pacific Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 9.1. China Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
• 9.2. China Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 10.1. India Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 11.1. Japan Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
• 11.2. Japan Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 12.1. Australia Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 13.1. Indonesia Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 14.1. South Korea Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
• 14.2. South Korea Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 15.1. Western Europe Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
• 15.2. Western Europe Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 16.1. UK Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 17.1. Germany Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 18.1. France Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 19.1. Italy Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 20.1. Spain Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 21.1. Eastern Europe Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
• 21.2. Eastern Europe Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 22.1. Russia Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 23.1. North America Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
• 23.2. North America Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 24.1. USA Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
• 24.2. USA Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 25.1. Canada Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
• 25.2. Canada Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 26.1. South America Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
• 26.2. South America Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 27.1. Brazil Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 28.1. Middle East Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
• 28.2. Middle East Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Autologous Stem Cell And Non-Stem Cell Based Therapies Market

• 29.1. Africa Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
• 29.2. Africa Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Autologous Stem Cell And Non-Stem Cell Based Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Competitive Landscape And Company Profiles

• 30.1. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Competitive Landscape
• 30.2. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Other Major And Innovative Companies

• 31.1. Stemcell Technologies Inc.
• 31.2. Dendreon Corporation
• 31.3. Vericel Corporation
• 31.4. Sangamo Therapeutics Inc.
• 31.5. NEOSTEM
• 31.6. Orgenesis Inc.
• 31.7. Adaptimmune Therapeutics
• 31.8. Stempeutics Research Pvt Ltd.
• 31.9. MEDIPOST
• 31.10. Castle Creek Biosciences Inc.
• 31.11. BrainStorm Cell Limited
• 31.12. Athersys Inc.
• 31.13. Cytori Therapeutics Inc.
• 31.14. Opexa Therapeutics
• 31.15. Gamida Cell

32. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Autologous Stem Cell And Non-Stem Cell Based Therapies Market

34. Recent Developments In The Autologous Stem Cell And Non-Stem Cell Based Therapies Market

35. Autologous Stem Cell And Non-Stem Cell Based Therapies Market High Potential Countries, Segments and Strategies

• 35.1 Autologous Stem Cell And Non-Stem Cell Based Therapies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Autologous Stem Cell And Non-Stem Cell Based Therapies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Autologous Stem Cell And Non-Stem Cell Based Therapies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer